Postoperative Treatment With Docetaxel, Cisplatin, and Capecitabine (DCX) and Chemoradiotherapy (CRT) With Capecitabine for Resected Gastric Adenocarcinoma. (February 2015)

• Record Type: Journal Article
• Authors: Saridaki, Zacharenia; Lambrodimou, Georgia; Kachris, Stefanos; Makrantonakis, Paris; Boukovinas, Ioannis; Polyzos, Aris; Anagnostopoulos, Athanasios; Athanasiadis, Athanasios; Stoltidis, Dimitris; Georgoulias, Vassilis; Souglakos, John
• Is Part Of: American journal of clinical oncology. Volume 38:Number 1(2015)
• Publication Date: 2015-02
• Subjects: Cancer -- Treatment -- Periodicals; Oncology -- Periodicals; Tumors -- Periodicals; 616.994005
• DOI: 10.1097/COC.0b013e3182893f13
• Languages: English
• ISSNs: 0277-3732

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <sec> <title>Introduction:</title> <p>We conducted a feasibility study on docetaxel/capecitabine/cisplatin (DCX) with chemoradiotherapy as adjuvant treatment for gastric cancer patients.</p> </sec> <sec> <title>Methods:</title> <p>Patients were scheduled to receive 2 cycles of DCX, followed by 50.4 Gy plus capecitabine as radiotherapy, followed by an additional 2-DCX cycles.</p> </sec> <sec> <title>Results:</title> <p>From the 40 enrolled patients, 26 (65%) completed treatment as per protocol and 14 (35%) discontinued with the treatment (patients' refusal: n=6; adverse events: n=8). There were 2 toxic deaths. Grade &gt;3 toxicity was 12.1% before and 13.3% after chemoradiotherapy. Disease progression was documented in 11 (27.5%) patients.</p> </sec> <sec> <title>Conclusions:</title> <p>No further development of this regimen is justified on the basis of poor tolerability in patients.</p> </sec> </abstract>